Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.83 USD
-0.10 (-3.41%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.84 +0.01 (0.35%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Income Statements
Fiscal Year end for Organogenesis falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 433 | 451 | 468 | 338 | 261 |
Cost Of Goods | 106 | 105 | 114 | 87 | 76 |
Gross Profit | 327 | 346 | 354 | 251 | 185 |
Selling & Adminstrative & Depr. & Amort Expenses | 314 | 324 | 281 | 224 | 214 |
Income After Depreciation & Amortization | 13 | 22 | 73 | 27 | -29 |
Non-Operating Income | 0 | 0 | -2 | 2 | -2 |
Interest Expense | 2 | 2 | 7 | 11 | 9 |
Pretax Income | 10 | 20 | 64 | 18 | -40 |
Income Taxes | 5 | 5 | -31 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5 | 16 | 95 | 18 | -40 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 5 | 16 | 95 | 18 | -40 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 36 | 40 | 90 | 35 | -20 |
Depreciation & Amortization (Cash Flow) | 23 | 18 | 17 | 7 | 9 |
Income After Depreciation & Amortization | 13 | 22 | 73 | 27 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 132.75 | 132.38 | 133.66 | 111.36 | 92.84 |
Diluted EPS Before Non-Recurring Items | 0.04 | 0.12 | 0.76 | 0.16 | -0.42 |
Diluted Net EPS (GAAP) | 0.04 | 0.12 | 0.71 | 0.16 | -0.44 |
Fiscal Year end for Organogenesis falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 130.23 | 109.98 | 99.65 | 108.53 | 117.32 |
Cost Of Goods | 29.20 | 28.70 | 27.77 | 25.79 | 26.32 |
Gross Profit | 101.04 | 81.28 | 71.88 | 82.74 | 91.00 |
SG&A, R&D, and Dept/Amort Expenses | 114.93 | 85.13 | 73.15 | 74.69 | 81.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.89 | -3.85 | -1.27 | 8.05 | 9.74 |
Non-Operating Income | -0.03 | 0.02 | -0.03 | 0.03 | 0.03 |
Interest Expense | 0.62 | 0.51 | 0.50 | 0.44 | 0.59 |
Pretax Income | -14.54 | -4.34 | -1.80 | 7.64 | 9.18 |
Income Taxes | 2.50 | -2.24 | -1.23 | 4.47 | 3.86 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.04 | -2.10 | -0.57 | 3.17 | 5.32 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.04 | -2.10 | -0.57 | 3.17 | 5.32 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 132.57 | 131.86 | 131.86 | 133.42 | 133.07 |
Diluted EPS Before Non-Recurring Items | -0.13 | -0.02 | 0.00 | 0.02 | 0.04 |
Diluted Net EPS (GAAP) | -0.13 | -0.02 | 0.00 | 0.02 | 0.04 |